Skip to main content
TipRanks
Go Ultimate75% OFF

Enorama Pharma AB (ERMA) AI Stock Analysis

0 Followers
SE:ERMA

Enorama Pharma AB

(Nasdaq OMX AB:ERMA)

Select Model
Rating:42Neutral
Price Target:SEK 0.50â–¼(-15.82% Downside)
Action:upgraded
Date:11/17/26

The overall score is severely depressed by the company's dire financial state, marked by insolvency, collapsing revenues, and massive cash burn. This is the most significant risk factor. Valuation offers no support due to negative earnings and no dividend. The only mildly supportive factor is a technical picture showing the price above longer-term moving averages, but this is overshadowed by the fundamental weaknesses.

Positive Factors
Low LeverageMinimal debt reduces interest burden and near-term refinancing pressure, giving Enorama more flexibility than a highly leveraged peer. If the company improves commercialization, this cleaner liability profile could help preserve cash for product development and market expansion.
Negative Factors
Persistent UnprofitabilityRepeated operating and net losses show that current revenue does not cover the company’s cost base, while deeply negative margins limit internal funding capacity. Without a sustained improvement in sales or economics, profitability remains uncertain and business scale-up is financially difficult.

Enorama Pharma AB (ERMA) vs. iShares MSCI Sweden ETF (EWD)

-100%-75%-50%-25%0%25%SE:ERMA-77.30%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 38.49M
Dividend Yield
―
Average Volume (3M)
134.13K
Price to Earnings (P/E)
-0.7
Beta (1Y)
0.59
Revenue Growth
-87.19%
EPS Growth
29.58%
Country
Sweden
Employees
4
Sector
General
Sector Strength
55
Industry
Medical - Pharmaceuticals

Enorama Pharma AB Business Overview & Revenue Model

Company Description

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based i...

Enorama Pharma AB Financial Statement Overview

Summary

Financial performance is critically weak. Revenue has collapsed, gross margins are deeply negative, and net losses are widening. The balance sheet shows negative equity, indicating insolvency, and operating cash flow is heavily negative, requiring constant external funding. The only marginal positive is a slight deceleration in cash burn.

Income Statement

8Very Negative

Balance Sheet

1Very Negative

Cash Flow

5Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.45M2.74M15.77M1.36M6.85M11.04M
Gross Profit-42.79M-61.78M3.70M-3.90M-616.00K2.13M
EBITDA-54.13M-61.65M-20.41M-40.18M-37.22M-25.56M
Net Income-59.68M-75.14M-43.81M-44.61M-41.78M-28.54M
Balance Sheet
Total Assets6.95M8.26M15.89M34.38M48.72M50.93M
Cash, Cash Equivalents and Short-Term Investments2.10M3.04M2.08M6.15M4.14M12.20M
Total Debt000436.00K1.91M3.79M
Total Liabilities57.39M31.71M8.09M14.85M17.20M29.58M
Stockholders Equity-50.44M-23.45M7.80M19.54M31.52M21.35M
Cash Flow
Free Cash Flow-53.05M-59.26M-35.70M-41.35M-32.96M-31.99M
Operating Cash Flow-53.05M-59.26M-35.70M-41.35M-32.96M-30.16M
Investing Cash Flow00000-1.82M
Financing Cash Flow51.67M50.69M35.29M41.86M25.34M39.51M

Enorama Pharma AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.59

Price Trends

50DMA0.75Negative
100DMA0.63Negative
200DMA0.56Negative

Market Momentum

MACD-0.06Positive
RSI41.03Neutral
STOCH18.02Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ERMA, the sentiment is Negative. The current price of 0.59 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.75, and above the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 41.03 is Neutral, neither overbought nor oversold. The STOCH value of 18.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ERMA.

Enorama Pharma AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:ERMA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:ENZYSE:ENZY46NeutralSEK 551.01M-13.87――-2.36%23.44%
SE:ONCOSE:ONCO44NeutralSEK 729.43M-2.60――65.37%43.28%
SE:ERMASE:ERMA42NeutralSEK 38.49M-0.72――-87.19%29.58%
SE:ORXSE:ORX41NeutralSEK 351.27M-0.09-115.03%―-97.68%-83.26%

* General Sector Average

Performance Comparison

-50%0%50%SE:ERMASE:ORXSE:ONCOSE:ENZYSE:DICOTSE:CINPHADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ERMA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ERMAEnorama Pharma AB0.59-2.01-77.38%
SE:ORXOrexo AB0.98-15.80-94.14%
SE:ONCOOncopeptides AB1.64-3.30-66.83%
SE:ENZYEnzymatica AB2.320.4826.09%
SE:DICOTDicot Pharma AB0.20-0.20-50.13%
SE:CINPHACinclus Pharma Holding AB11.22-5.78-34.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026